Skip to main content
S&P 5007,720.39-0.30%DOW52,342.56-0.25%NASDAQ26,184.72-1.38%BTC$77,045.00-4.95%ETH$2,215.83-5.85%GOLD$4,026.60-0.12%OIL$102.79+0.77%
Smart Investors Daily
SID Premium
AL

NASDAQ · ALVO

Alvotech

Healthcare · Drug Manufacturers - Specialty & Generic

$4.89

Down-$0.05 (-1.01%)

Updated Oct 30, 2026, 6:42 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.24B
P/E ratio
17.23
Dividend yield
0.00%
52-week range
$2.94 – $8.01
Volume
373.36K
Avg. volume
511.3K

Price performance · ALVO

ALVO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

ALVO closed at $4.89 after 21 trading sessions, down 12.99% for the selected period.

Last close
$4.89
Period change
-12.99%
Period low
$4.58
Period high
$6.14
Daily close
View OHLC price history
ALVO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$4.95$5.00$4.845$4.89373.36K
Oct 28, 2026$4.77$4.97$4.735$4.94627.92K
Oct 27, 2026$4.62$4.765$4.60$4.75733.47K
Oct 26, 2026$4.57$4.64$4.52$4.62584.89K
Oct 23, 2026$4.78$4.78$4.565$4.58666.2K
Oct 22, 2026$5.07$5.07$4.79$4.79927K
Oct 21, 2026$5.14$5.24$5.115$5.13480.53K
Oct 20, 2026$5.40$5.45$5.085$5.121.3M
Oct 19, 2026$5.13$5.15$5.0203$5.03907.73K
Oct 16, 2026$5.27$5.30$4.95$5.001.06M
Oct 15, 2026$5.15$5.39$5.1309$5.311.16M
Oct 14, 2026$5.32$5.51$5.15$5.171.06M
Oct 13, 2026$5.51$5.64$5.311$5.381.21M
Oct 12, 2026$5.79$5.89$5.44$5.50841.04K
Oct 9, 2026$5.67$5.805$5.565$5.78707.14K
Oct 8, 2026$5.83$5.83$5.605$5.67668.88K
Oct 7, 2026$6.10$6.14$5.845$5.85864.57K
Oct 6, 2026$6.07$6.17$6.00$6.141.22M
Oct 5, 2026$5.99$6.53$5.90$6.112.9M
Oct 2, 2026$5.61$5.70$5.43$5.45750.93K
Oct 1, 2026$5.81$5.82$5.46$5.621.2M

Latest ALVO news

The latest Smart Investors Daily articles mentioning ALVO.

Stock researchCompany · Overview

ALVO research

Overview

Company profile and research snapshot.

Company profile

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.60
Implied upside
—
Analysts
—
ALVO recent ratings
DateFirmRatingTarget
Sep 16, 2026BarclaysOverweight—
Aug 24, 2026B of A SecuritiesBuy—
Aug 14, 2026Evercore ISI GroupOutperform—
Mar 24, 2026UBSBuy—
Mar 24, 2026BarclaysUnderweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 14, 2026

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal diseases REYKJAVIK, Iceland and LONDON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma Holdc

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By